Collins Stewart initiates coverage on BioMarin Pharmaceuticals (Nasdaq: BMRN) with a Buy and a $39 price target. BioMarin is currently ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE